(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 0.61% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 8.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
10x Genomics's revenue in 2025 is $624,662,000.On average, 8 Wall Street analysts forecast TXG's revenue for 2025 to be $72,678,218,333, with the lowest TXG revenue forecast at $70,638,138,363, and the highest TXG revenue forecast at $74,982,297,063. On average, 8 Wall Street analysts forecast TXG's revenue for 2026 to be $76,891,732,124, with the lowest TXG revenue forecast at $71,586,268,238, and the highest TXG revenue forecast at $82,537,783,963.
In 2027, TXG is forecast to generate $84,504,722,485 in revenue, with the lowest revenue forecast at $77,208,062,728 and the highest revenue forecast at $94,484,220,388.